Crossref
Thyroid and liver dysfunction in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab
Medical Research Journal · 15.01.2026 · 11
DOI: 10.5603/mrj.109896 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Research Journal, online erschienen am 15.01.2026. Verfasst von Emilia Barańska-Bała und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Barańska-Bała, E., Małachowska, P., Wileński, S., Koper, A., & Koper, K. (2026). Thyroid and liver dysfunction in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab. Medical Research Journal, 11(0). https://doi.org/10.5603/mrj.109896
Vancouver
Barańska-Bała E, Małachowska P, Wileński S, Koper A, Koper K. Thyroid and liver dysfunction in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab. Medical Research Journal. 2026;11(0). doi:10.5603/mrj.109896
BibTeX
@article{BaraskaBaa2026,
author = {Barańska-Bała, Emilia and Małachowska, Paulina and Wileński, Sławomir and Koper, Agnieszka and Koper, Krzysztof},
title = {Thyroid and liver dysfunction in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab},
journal = {Medical Research Journal},
year = {2026},
volume = {11},
number = {0},
doi = {10.5603/mrj.109896}
}
EUVIMED